L
Laurence E. Burgess
Researcher at University of Texas at Austin
Publications - 57
Citations - 1127
Laurence E. Burgess is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Lactol & Carboxylic acid. The author has an hindex of 16, co-authored 57 publications receiving 904 citations. Previous affiliations of Laurence E. Burgess include Icos & Celgene.
Papers
More filters
Journal ArticleDOI
Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists.
Shelley Allen,Brad Newhouse,Aaron S. Anderson,Benjamin Fauber,Andrew J. Allen,David Chantry,Christine D. Eberhardt,Joshua Odingo,Laurence E. Burgess +8 more
TL;DR: Lead optimization efforts resulted in defined structure-activity relationships and the identification of potent antagonists (compounds 90 and 91) that inhibited the chemotaxis of Th2 T-cells in vitro.
Journal ArticleDOI
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Fell Jay Bradford,John P. Fischer,Brian R. Baer,Joshua Ballard,James F. Blake,Karyn Bouhana,Barbara J. Brandhuber,David Briere,Laurence E. Burgess,Michael Burkard,Harrah Chiang,Mark Joseph Chicarelli,Kevin Davidson,John Gaudino,Jill Hallin,Lauren Hanson,Kenneth Hee,Hicken Erik James,Ronald Jay Hinklin,Matthew A. Marx,Macedonio J. Mejia,Peter Olson,Pavel Savechenkov,Niranjan Sudhakar,Tony Pisal Tang,Guy Vigers,Henry J. Zecca,James G. Christensen +27 more
TL;DR: A series of tetrahydropyridopyrimidines are discovered as irreversible covalent inhibitors of KRAS-G12C with in vivo activity and the PK/PD and efficacy of compound 13 will be highlighted.
Journal ArticleDOI
Chemokines in allergy.
TL;DR: This mini-review will focus on new research involving CCR3, CCR4 and CCR8, which are preferentially expressed by Th2 cells, mast cells and eosinophils and therefore represent therapeutic targets for allergy.
Patent
5, 7-substituted-imidazo [1, 2-c]pyrimidines as inhibitors of jak kinases
Boys Mark Laurence,Laurence E. Burgess,Robert D. Groneberg,Darren Harvey,Huang Lily,Timothy Kercher,Christopher F. Kraser,Laird Ellen,Eugene Tarlton,Qian Zhao +9 more
TL;DR: In this paper, the authors describe a class of inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
Journal ArticleDOI
Novel approach to the ansamycin antibiotics macbecin I and herbimycin A. A formal total synthesis of (+)-macbecin I
TL;DR: The asymmetric synthesis of 25 and 29, which constitutes the C(3) −C(15) segment of the stereochemically complex ansa chain of (+)-macbecin I (1) and herbimycin A (2), respectively, have been achieved as mentioned in this paper.